Adage Capital Partners GP L.L.C. Acquires New Position in Atyr PHARMA INC (NASDAQ:ATYR)

Adage Capital Partners GP L.L.C. bought a new position in Atyr PHARMA INC (NASDAQ:ATYR) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 1,000,000 shares of the company’s stock, valued at approximately $3,620,000.

Several other institutional investors and hedge funds have also made changes to their positions in ATYR. Charles Schwab Investment Management Inc. purchased a new position in Atyr PHARMA during the fourth quarter worth approximately $144,000. American Century Companies Inc. acquired a new stake in shares of Atyr PHARMA in the 4th quarter worth $319,000. Victory Capital Management Inc. purchased a new position in shares of Atyr PHARMA during the 4th quarter worth $37,000. Raymond James Financial Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter valued at about $39,000. Finally, D.A. Davidson & CO. purchased a new stake in shares of Atyr PHARMA in the fourth quarter valued at about $141,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Atyr PHARMA Stock Up 3.4 %

Shares of NASDAQ ATYR opened at $3.38 on Wednesday. Atyr PHARMA INC has a 52-week low of $1.42 and a 52-week high of $4.66. The business’s 50 day moving average is $3.32 and its two-hundred day moving average is $3.38. The firm has a market cap of $300.34 million, a price-to-earnings ratio of -3.60 and a beta of 0.95. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. Research analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current year.

Analyst Upgrades and Downgrades

ATYR has been the topic of a number of analyst reports. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Friday, March 14th. Leerink Partners started coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on Atyr PHARMA in a research report on Monday, January 6th. They issued an “overweight” rating on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Atyr PHARMA has a consensus rating of “Buy” and a consensus target price of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.